Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Savolitinib is effective in patients with MET-mutated NSCLC

Savolitinib is effective in patients with MET-mutated NSCLC

Presented By
Dr Shun Lu, Shanghai Chest Hospital, China
Presented by
Shun Lu Shanghai Chest Hospital, China
Conference
ELCC 2022
Trial
Phase 2
Doi
https://doi.org/10.55788/fbfccb48
The final results of a phase 2 study confirmed the selective MET tyrosine kinase inhibitor savolitinib to be effective in patients with MET exon 14 skipping-mutated non-small cell lung cancer (NSCLC), irrespective of the subgroup. A MET exon 14 skipping mutation is present in about 3% of patients with NSCLC [1]. Savolitinib is a highly selective MET tyrosine kinase inhibitor that is approved in China for the treatment of MET exon 14 skipping-mutated NSCLC based on (interim) results of a phase 2 study (NCT02897479) [2]. Dr Shun Lu (Shanghai Chest Hospital, China) presented the final results of this study [3]. This multicentre, open-label, phase 2 trial, enrolled 70 patients with unresectable or metastatic MET exon 14 skipping-mutated NSCLC; 25 patients were diagnosed with pulmonary sarcomatoid carcinoma (P...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on